Canakinumab as first-line biological therapy in Still’s disease and differences between the systemic and the chronic-articular courses: Real-life experience from the international AIDA registry

OBJECTIVE: Interleukin (IL)-1 inhibitors are largely employed in patients with Still’s disease; in cases with refractory arthritis, IL-6 inhibitors have shown to be effective on articular inflammatory involvement. The aim of the present study is to assess any difference in the effectiveness of the I...

Descripción completa

Detalles Bibliográficos
Autores principales: Vitale, Antonio, Caggiano, Valeria, Maggio, Maria Cristina, Lopalco, Giuseppe, Emmi, Giacomo, Sota, Jurgen, La Torre, Francesco, Ruscitti, Piero, Bartoloni, Elena, Conti, Giovanni, Fabiani, Claudia, Mattioli, Irene, Gaggiano, Carla, Cardinale, Fabio, Dagna, Lorenzo, Campochiaro, Corrado, Giacomelli, Roberto, Balistreri, Alberto, Laskari, Katerina, Tufan, Abdurrahman, Ragab, Gaafar, Almaghlouth, Ibrahim A., Więsik-Szewczyk, Ewa, Pereira, Rosa Maria, Frediani, Bruno, Iannone, Florenzo, Sfikakis, Petros P., Cantarini, Luca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813488/
https://www.ncbi.nlm.nih.gov/pubmed/36619631
http://dx.doi.org/10.3389/fmed.2022.1071732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813488/
https://www.ncbi.nlm.nih.gov/pubmed/36619631
http://dx.doi.org/10.3389/fmed.2022.1071732

Ejemplares similares